Catalyst Wire Dossier Catalyst Wire Dossier

Efgartigimod IV

efgartigimod alfa · argenx
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Efgartigimod IV, covering 2026-04-23 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod [Phase 2]

See pricing